RecruitingNCT07466602

cfDNA Methylation for Liver Cancer Recurrence Detection

Clinical Study on the Combined Detection of Plasma GNB4 and Riplet Gene Methylation for Monitoring Primary Liver Cancer Recurrence

Sponsor

Wuhan Ammunition Life-tech Co., Ltd

Enrollment

500 participants

Start Date

Sep 2, 2025

Study Type

OBSERVATIONAL

Conditions

Primary Liver Cancer

Summary

Through follow-up testing of patients with primary liver cancer who underwent hepatectomy, liver transplantation, ablation therapy, or transarterial chemoembolization (TACE), a blinded comparative trial was conducted at each monitoring site. This trial evaluated the combined methylation detection kit for GNB4 and Riplet genes (fluorescent PCR method) against the clinical reference standard (defined as the physician's comprehensive diagnosis based on clinical guidelines and other criteria). The study evaluated the clinical performance of the assay in diagnosing primary liver cancer recurrence and validated the clinical efficacy of methylation detection kits for monitoring recurrence after primary liver cancer treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is exploring whether a blood test that detects tiny fragments of tumor DNA can predict if liver cancer will come back after treatment. The goal is to find a more accurate way to monitor patients after surgery or other liver cancer treatments. **You may be eligible if...** - You have been diagnosed with primary liver cancer (cancer that started in the liver) - You are able to undergo standard liver cancer treatments such as surgery, liver transplant, ablation (heat/cold treatment), or a procedure called TACE - Your tumor showed a positive result on a special methylation test before treatment **You may NOT be eligible if...** - You have another active cancer in addition to liver cancer - You are not a candidate for surgery, transplant, ablation, or TACE - Your tumor tested negative on the methylation screening test before treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTplasma GNB4 and Riplet genes methylation detection

Liver cancer patients undergo methylation testing at different follow-up time points after treatment

Locations(1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07466602

Related Trials

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

NCT0648645427 locations

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

NCT063424145 locations

Y-90 Treatment Response Using Transarterial Radioembolization

NCT071458011 location

The Dragon PLC Trial (DRAGON-PLC)

NCT0691464855 locations

Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver Resection

NCT069050151 location